BIOLINERX LTD/S (BLRX) Receives “Buy” Rating from Oppenheimer

Share on StockTwits

Oppenheimer reaffirmed their buy rating on shares of BIOLINERX LTD/S (NASDAQ:BLRX) in a research note published on Tuesday.

Several other equities research analysts also recently commented on BLRX. Maxim Group set a $2.00 price objective on BIOLINERX LTD/S and gave the stock a buy rating in a report on Wednesday, December 12th. HC Wainwright set a $4.00 price objective on BIOLINERX LTD/S and gave the stock a buy rating in a report on Tuesday, December 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $2.50.

NASDAQ BLRX opened at $0.46 on Tuesday. BIOLINERX LTD/S has a one year low of $0.38 and a one year high of $1.84. The stock has a market capitalization of $46.79 million, a P/E ratio of -1.71 and a beta of 1.70.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new stake in BIOLINERX LTD/S in the 4th quarter worth about $25,000. Menta Capital LLC bought a new stake in BIOLINERX LTD/S in the 4th quarter worth about $33,000. Finally, ETF Managers Group LLC increased its holdings in BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after buying an additional 166,386 shares in the last quarter. Institutional investors own 33.79% of the company’s stock.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

See Also: How is a Moving Average Calculated?

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Sherwin-Williams Co  Holdings Cut by Daiwa SB Investments Ltd.
Sherwin-Williams Co Holdings Cut by Daiwa SB Investments Ltd.
Appleton Partners Inc. MA Has $1.77 Million Holdings in JPMorgan Diversified Alternatives ETF
Appleton Partners Inc. MA Has $1.77 Million Holdings in JPMorgan Diversified Alternatives ETF
Aull & Monroe Investment Management Corp Buys 1,350 Shares of Target Co.
Aull & Monroe Investment Management Corp Buys 1,350 Shares of Target Co.
Appleton Partners Inc. MA Has $1.40 Million Position in Morgan Stanley
Appleton Partners Inc. MA Has $1.40 Million Position in Morgan Stanley
Daiwa SB Investments Ltd. Acquires Shares of 2,200 ISHARES INC/EDGE MSCI MIN VOLAT
Daiwa SB Investments Ltd. Acquires Shares of 2,200 ISHARES INC/EDGE MSCI MIN VOLAT
Daiwa SB Investments Ltd. Sells 370 Shares of Micron Technology, Inc.
Daiwa SB Investments Ltd. Sells 370 Shares of Micron Technology, Inc.


 
© 2006-2019 Zolmax.